Top Page
Shuttle Pharmaceuticals Holdings, Inc.
(NASDAQ:SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) vs. SPDR S&P 500 ETF (SPY)
Shuttle Pharmaceuticals Holdings, Inc. Business Overview & Revenue Model
Shuttle Pharmaceuticals Holdings, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.80K | 0.00 | 0.00 | -5.97K | -60.83K | -54.95K |
| EBITDA | -10.72M | -7.78M | -3.99M | -4.32M | -1.04M | -711.15K |
| Net Income | -10.71M | -9.14M | -6.59M | -5.00M | -1.15M | -805.73K |
Balance Sheet | ||||||
| Total Assets | 3.54M | 2.51M | 5.95M | 8.65M | 651.64K | 544.05K |
| Cash, Cash Equivalents and Short-Term Investments | 2.09M | 1.92M | 5.46M | 8.42M | 504.75K | 117.15K |
| Total Debt | 667.33K | 1.17M | 1.09M | 748.30K | 978.88K | 874.28K |
| Total Liabilities | 2.15M | 1.80M | 1.90M | 975.68K | 2.28M | 2.23M |
| Stockholders Equity | 1.39M | 709.15K | 4.06M | 7.68M | -1.63M | -1.69M |
Cash Flow | ||||||
| Free Cash Flow | -11.20M | -7.33M | -5.60M | -2.67M | -300.34K | -37.65K |
| Operating Cash Flow | -11.20M | -7.33M | -5.58M | -2.67M | -300.34K | -26.83K |
| Investing Cash Flow | 0.00 | 2.92M | -2.83M | 0.00 | 0.00 | -10.82K |
| Financing Cash Flow | 13.14M | 3.76M | 2.57M | 10.58M | 687.93K | 70.07K |
Shuttle Pharmaceuticals Holdings, Inc. Technical Analysis
Shuttle Pharmaceuticals Holdings, Inc. Risk Analysis
Shuttle Pharmaceuticals Holdings, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.38M | ― | 2.66% | ― | -27.81% | ― | |
50 Neutral | $6.43M | -1.72 | -76.14% | ― | 25.02% | 55.11% | |
47 Neutral | $6.82M | ― | ― | ― | ― | ― | |
43 Neutral | $3.33M | ― | ― | ― | ― | ― | |
42 Neutral | $6.80M | -1.31 | -42.47% | ― | -26.92% | 69.90% | |
32 Underperform | $2.89M | -0.08 | -9999.00% | ― | ― | 79.31% |
Shuttle Pharmaceuticals Holdings, Inc. Corporate Events
On December 23, 2025, Shuttle Pharmaceuticals Holdings, Inc. amended an existing asset purchase agreement involving its Canadian subsidiary 1563868 B.C. Ltd., Canadian seller 1542770 BC Ltd., and a seller guarantor, accelerating part of the first installment payment by issuing 320,496 shares of common stock. The transaction, which closed the same day, resulted in the seller receiving shares equal to 19.99% of Shuttle’s outstanding common stock at a deemed value of $1.76 per share, with the remaining portion of the first installment to be paid in cash under the original terms, signaling a material equity-based consideration structure executed under securities law exemptions for unregistered offerings.
On November 21, 2025, Shuttle Pharmaceuticals Holdings, Inc. announced the resignation of Timothy Lorber as Chief Financial Officer. In connection with his resignation, a Separation Agreement was established, allowing Mr. Lorber to provide part-time services until December 4, 2025, and remain available for consultation until February 8, 2026. Christopher Cooper, the Interim CEO, has taken over the CFO role while the company searches for a permanent replacement. The agreement includes a retention bonus for Mr. Lorber and the vesting of restricted stock units, reflecting a structured transition plan.
On November 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. finalized an Asset Purchase Agreement with its subsidiary and other parties, acquiring substantial assets and liabilities from a Canadian corporation. The transaction involved a cash payment of $3 million on the closing date, with additional payments and potential milestone-based contributions outlined in the agreement. This strategic acquisition is expected to enhance Shuttle Pharmaceuticals’ capabilities in drug discovery, leveraging advanced AI models to accelerate the process, which may strengthen its position in the pharmaceutical industry.
On October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. received a termination notice from Theradex Systems, Inc. regarding their master agreement, leading to a settlement where Shuttle Pharmaceuticals will pay $300,000 to Theradex to settle outstanding liabilities. Consequently, Shuttle Pharmaceuticals has decided to discontinue its clinical trials of Ropidoxuridine, expecting to incur additional expenses related to trial closeout activities, with most charges anticipated in the fourth quarter of 2025.
Shuttle Pharmaceuticals Holdings, Inc. reported a stockholders’ equity of $1,394,161 for the quarter ended September 30, 2025, falling short of the Nasdaq’s requirement of $2,500,000. However, the company believes it has regained compliance following a private placement on November 4, 2025, which raised approximately $2.5 million. Nasdaq will continue to monitor the company’s compliance, and failure to maintain the required equity could result in delisting.
On November 3, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement to issue and sell a pre-funded warrant for 625,156 shares of common stock, raising approximately $2.5 million in a private placement. The offering closed on November 4, 2025, and includes provisions for the exercise of the warrant and filing of a registration statement with the SEC. The transaction was facilitated by WestPark Capital, Inc. as the placement agent, with the company agreeing to certain restrictions on issuing additional shares for a period following the offering.
On October 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a binding term sheet with 1542770 BC Ltd. to acquire substantially all of Molecule’s assets and liabilities for $10 million, payable in cash and company stock, contingent on certain milestones. Earlier, on October 15, 2025, Shuttle received a termination notice from Theradex Systems, Inc., its primary contract research organization, demanding payment of $1.091 million and threatening to cease services if unpaid within 30 days, highlighting potential operational disruptions.